CALIBRATE: A phase 3, randomized, open-label study evaluating the efficacy and safety of encaleret (CLTX-305) compared to standard of care in participants with autosomal dominant hypocalcemia type 1 [NCT05680818]
Rejnmark L, Mannstadt M, Brandi M, Ozono K, Tebben P, Mathew A, Roberts M, Adler S, Gafni R. CALIBRATE: A phase 3, randomized, open-label study evaluating the efficacy and safety of encaleret (CLTX-305) compared to standard of care in participants with autosomal dominant hypocalcemia type 1 [NCT05680818]. Endocrine Abstracts 2024 DOI: 10.1530/endoabs.99.oc2.6.Peer-Reviewed Original ResearchOpen-label study